Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Purpose: To compare the efficacy of photodynamic therapy (PDT) in eyes with polypoidal choroidal vasculopathy (PCV) associated with and without pachychoroid phenotypes (pachychoroid PCV and nonpachychoroid PCV, respectively).
Design: Retrospective chart review.
Participants: Patients previously diagnosed with PCV and initially treated with PDT.
Methods: Patients were classified as having pachychoroid- or nonpachychoroid-driven conditions. The long-term visual outcome and its associated factors were investigated.
Main Outcome Measures: Visual acuity (VA) outcomes at 1, 2, 3, 4, and 5 years after initial PDT in pachychoroid and nonpachychoroid PCV.
Results: Of the 158 eyes, 88 (55.7%) met the criteria for pachychoroid PCV; 70 (44.3%) did not (nonpachychoroid PCV). In cases of pachychoroid PCV, VA improved significantly at 1 year (P = 0.042) and maintained baseline level at 5 years (P = 0.38). By contrast, VA continued to deteriorate in the nonpachychoroid PCV group during the follow-up period and had already declined significantly by the second year (P = 0.022, compared with baseline). Despite no difference in baseline VA between pachychoroid and nonpachychoroid PCV groups (P = 0.11), the VA at 5 years was significantly better in the pachychoroid PCV group compared with the nonpachychoroid PCV group (0.54±0.47 vs. 0.93±0.63, respectively; P = 0.23 × 10). The incidence of massive submacular hemorrhage (SMH) or vitreous hemorrhage (VH) was not different between groups at 5 years (P = 0.67), and their occurrence was associated with decreased VA in both the nonpachychoroid and pachychoroid PCV groups (coefficient β, 0.361 and 0.481; P = 0.59 × 10 and P < 1.0 × 10, respectively).
Conclusions: Five years after PDT treatment, VA was maintained at the baseline level in the pachychoroid PCV group but not in the nonpachychoroid PCV group. Massive SMH or VH during the follow-up period affected the final visual outcomes in both conditions.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.oret.2019.06.013 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Photodynamic therapy on chronic pathology during the post-COVID19 and worldwide shortage of verteporfin (Visudyne®) era.
Photodiagnosis Photodyn Ther
July 2025
Medical Ophthalmology Foundation of V.C. (FOM) 46015. Valencia, Spain; Universidad CEU Cardenal Herrera, School of Health Sciences 46115. Alfara del Patriarca, Spain.
Background: We analyze COVID19 pandemia and shortage of verteporfin (Visudyne®) consequences in photodynamic therapy (PDT) treated patients.
Material And Methods: A retrospective study was performed in 97 patients treated with PDT last 3 years. We used HALF DOSE PDT for chronic central serous chorioretinopathy (cCSCR) (n = 84) and FULL DOSE for polypoidal choroidal vasculopathy (PCV) (n = 13).
Analysis of cytokine profiles in aqueous humor based on optical coherence tomography in pachychoroid spectrum diseases.
Sci Rep
July 2025
Department of Ophthalmology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China.
This study investigated cytokine profiles in the aqueous humor (AH) of 172 eyes with central serous chorioretinopathy (CSC, n = 65), pachychoroid neovasculopathy (PNV, n = 24), polypoidal choroidal vasculopathy (PCV, n = 43), and controls (n = 40). AH samples were analyzed using a multiplex bead assay for cytokines including vascular endothelial growth factor (VEGF), interleukin-6 (IL-6), IL-8, IL-10, IP-10, and MCP-1. Results showed no significant differences in IL-6 (P = 0.
View Article and Find Full Text PDFReduction in choroidal thickness associated with the progression of pachychoroid spectrum diseases.
Jpn J Ophthalmol
June 2025
Department of Ophthalmology, Gunma University Graduate School of Medicine, 3-39-15 Showa-machi, Maebashi, Gunma, 371-8511, Japan.
Purpose: Pachychoroid spectrum diseases reportedly progress from central serous chorioretinopathy (CSC) to pachychoroid neovasculopathy (PNV) and polypoidal choroidal vasculopathy (PCV). We investigated and compared choroidal thicknesses in the macular and peripheral areas among eyes with CSC, PNV, and PCV, as well as in normal control eyes.
Study Design: Retrospective case-control study.
Incidence of recurrence and development of polypoidal lesions following half-dose and two-thirds dose photodynamic therapy for pachychoroid neovasculopathy.
Sci Rep
May 2025
Department of Ophthalmology, Nihon University School of Medicine, Nihon University Hospital, Tokyo, Japan.
The purpose of this study was to determine the recurrence rate, factors, incidence of polypoidal lesions, and risk factors for developing polypoidal lesions after a reduced dose photodynamic therapy (PDT) for pachychoroid neovasculopathy (PNV) without polypoidal lesions. This study is an observational case-control study. The study included 105 patients (77 men, 28 women; mean age, 61.
View Article and Find Full Text PDFFundus Autofluorescence (FAF) Alteration in Polypoidal Choroidal Vasculopathy (PCV) and Typical Neovascular Age Related Macular Degeneration (tAMD).
Retina
May 2025
Singapore Eye Research Institute, Singapore National Eye Centre, Singapore.
Purpose: To characterize and evaluate differences in fundus autofluorescence (FAF) alteration in polypoidal choroidal vasculopathy (PCV) and typical neovascular age related macular degeneration (tAMD).
Methods: We used multimodal imaging to delineate the area of macular neovascularization (MNV) and extent of subretinal fluid (SRF). Macular FAF alteration was categorized to those limited to the area of the neovascular lesion (zone 1), area beyond zone 1 affected by subretinal fluid or pigment epithelial detachment (zone 2), and area beyond zone 2 (zone 3).